Skip to main content
. Author manuscript; available in PMC: 2013 Jul 22.
Published in final edited form as: Endocr Relat Cancer. 2012 Jan 9;19(1):29–38. doi: 10.1530/ERC-11-0155

Figure 3.

Figure 3

Cell signaling inhibition of combination therapy. Western blots were performed at the listed concentrations for each cell line after 3 h of exposure to confirm that the combinations of therapies were active in vitro. Each combination inhibited the expected targets; combined inhibition of Ret and Erk phosphorylation required the combination of AZD6244 and sorafenib in both the cell lines. Everolimus-induced Ret and Akt phosphorylation was enhanced by co-treatment with AZD6244. The arrows in the ERK blot point to the dual ERK bands.